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Backround: Neuroprotective strategies after cardiopulmonary resuscitation are currently the focus of experimental
and clinical research. Levosimendan has been proposed as a promising drug candidate because of its
cardioprotective properties, improved haemodynamic effects in vivo and reduced traumatic brain injury in vitro.
The effects of levosimendan on brain metabolism during and after ischaemia/hypoxia are unknown.
Methods: Transient cerebral ischaemia/hypoxia was induced in 30 male Wistar rats by bilateral common carotid
artery clamping for 15 min and concomitant ventilation with 6% O2 during general anaesthesia with urethane. After
10 min of global ischaemia/hypoxia, the rats were treated with an i.v. bolus of 24 μg kg-1 levosimendan followed
by a continuous infusion of 0.2 μg kg-1 min-1. The changes in the energy-related metabolites lactate, the lactate/
pyruvate ratio, glucose and glutamate were monitored by microdialysis. In addition, the effects on global
haemodynamics, cerebral perfusion and autoregulation, oedema and expression of proinflammatory genes in the
neocortex were assessed.
Results: Levosimendan reduced blood pressure during initial reperfusion (72 ± 14 vs. 109 ± 2 mmHg, p = 0.03) and
delayed flow maximum by 5 minutes (p = 0.002). Whereas no effects on time course of lactate, glucose, pyruvate
and glutamate concentrations in the dialysate could be observed, the lactate/pyruvate ratio during initial
reperfusion (144 ± 31 vs. 77 ± 8, p = 0.017) and the glutamate release during 90 minutes of reperfusion (75 ± 19 vs.
24 ± 28 μmolL-1) were higher in the levosimendan group. The increased expression of IL-6, IL-1ß TNFα and ICAM-1,
extend of cerebral edema and cerebral autoregulation was not influenced by levosimendan.
Conclusion: Although levosimendan has neuroprotective actions in vitro and on the spinal cord in vivo and has
been shown to cross the blood–brain barrier, the present results showed that levosimendan did not reduce the
initial neuronal injury after transient ischaemia/hypoxia.
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Patients under cardiac arrest undergo acute global
ischaemia and acute reperfusion injury due to the return
of spontaneous circulation. Although this reperfusion in-
jury affects all organs, the heart and brain are particu-
larly vulnerable. Neurological and cardiac complications* Correspondence: aroehl@ukaachen.de
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reproduction in any medium, provided the orfollowing cardiopulmonary resuscitation (CPR) are
closely associated and might aggravate cellular damage.
Cerebral ischaemia activates cellular processes, including
apoptosis, inflammation, inhibition of protein synthesis
and increased oxidative stress, that persist despite the
restoration of substrate delivery [1]. This initial neuronal
injury involves disruptions in brain metabolism and the
release of neurotransmitters, which activate neurotoxic
cascades that can be monitored by microdialysis [2-4].
Studies have previously demonstrated that ischaemic
postconditioning dramatically attenuates irreversibletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cerebral ischaemia-reperfusion injury due to ischaemic
postconditioning has been previously described [6].
Interestingly, studies have estimated that every minute
of lost cerebral perfusion in the human brain results in a
loss of neurons that is equivalent to the loss of neurons
after 3.6 years of the normal human ageing process [7].
Currently, the only valid form of therapy to improve
neurological outcome is to perform therapeutic
hypothermia 12 to 24 h following resuscitation [8]. Con-
comitant with the symptomatic therapy used to achieve
return of spontaneous circulation (ROSC), therapeutic
options employed to minimise the reperfusion injury
have to be considered.
The ideal pharmacological intervention would be
initiated during CPR and would exhibit cardiac and neu-
roprotective properties. Thus, a cardiac postconditioning
effect may only be attained prior to the time window be-
cause the cardiac postconditioning closes two minutes
after the re-establishment of spontaneous circulation [9].
The time frame for cerebral postconditioning has previ-
ously been described as a maximum of three minutes
following the onset of reperfusion [10], whereas expan-
sion of the penumbra after focal ischaemia may be
reduced within the first six hours after reperfusion.
Thus, sufficient effect-site concentrations of postcondi-
tioning agents should be made available at the start of
the reperfusion. Levosimendan is a novel inodilator that
enhances myocardial performance without resulting in
substantial changes in myocardial oxygen consumption
[11]. Levosimendan reduces myocardial injury if it is ap-
plied during ischaemia and early reperfusion [12]. Evi-
dence of levosimendan’s neuroprotective properties
include reduced cell death, inflammatory response and
lipid peroxidation in the spinal cord and improved func-
tion after transient ischaemia [13,14]. Currently, the
demonstration of a reduction of primary and secondary
injury after brain trauma has been limited to in vitro
models [15]. The protective effects of levosimendan are
mediated in the heart by activation of the PI3K pathway,
the inducible nitric oxide synthase and mitochondrial
ATP-dependent potassium channels (mKATP). This also
results in a clearly vasodilation [16-18]. The important
role of mKATP channels in cerebral ischaemia-reperfusion
injury and positive action of other activators (diazoxide)
on neuronal injury, spark hopes of neuroprotective effects
of levosimendan [19,20].
Based on the promising results of levosimendan, the
aim of the present study was to test the hypothesis that
levosimendan reduces initial ischaemic/hypoxic neur-
onal injury in the neocortex by postconditioning. We
employed a model of bilateral carotid occlusion with an
additional reduction of inspired oxygen concentration.
Changes in the metabolite and substrate levels,haemodynamics, regional perfusion, blood–brain barrier
dysfunction and local inflammatory response were mea-
sured by microdialysis, blood pressure measurements,
laser Doppler flow, and claudin 5/tight junction protein
and interleukin expression, respectively.
Methods
Instrumentation
All of the experiments were performed in accordance
with the German legislation governing animal studies
and followed the Guide for the Care and Use of Labora-
tory Animals [21]. Official permission for these studies was
granted from the governmental animal care and use office
(Landesamt für Natur-, Umwelt- und Verbraucherschutz
Nordrhein-Westfalen, Recklinghausen, Germany, Protocol
No. 8.87-50.10.55.09.064).
A previously established protocol was modified to in-
vestigate the effects of levosimendan on ischaemic brain
injury [22]. Thirty male Wistar rats (Charles River,
Sulzfeld, Germany, 300–350 g) were anaesthetised by an
intraperitoneal injection of 1.5 g/kg urethane (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany). After a
tracheotomy, the animals were ventilated with 30% oxy-
gen under the pressure-controlled mode (Pmax 13 mmHg,
PEEP 5 mm Hg) using a commercially available respir-
ator (Evita 2, Draeger, Luebeck, Germany) with a re-
spiratory frequency between 40 and 55 min-1. The right
femoral vein was catheterised with a 22 G cannula
(Leader Flex, Vygon, Germany) using Seldinger’s tech-
nique for continuous drug administration and blood
withdrawal. The mean arterial pressure (MAP) was mea-
sured with a 1.4 F pressure catheter (SPR-671, Millar
Instruments, Houston, Texas, USA) that was placed
through the right femoral artery. The heart rate (HR)
was calculated from the ECG signal. All of the data were
recorded using an acquisition and analysis system
(Power Lab 8/30, LabChart 6 Pro v 6.11; ADInstru-
ments, Colorado Springs, USA). A continuous infusion
of 4 ml kg-1 h-1 Ringers solution was administered to
compensate for the perioperative fluid loss. To maintain
body temperature, the animals were placed on a back-
coupled heating pad (MLT1403 and TCAT-2 Controller,
ML 295/R, Physitemp Instruments, USA). Both of the
common carotid arteries were identified in the supine
position and isolated from the attached vagal nerve. To
induce carotid clamping, a 2–0 silk suture (Fine Science
Tools, Heidelberg, Germany) was placed around each
common carotid artery.
In the prone position, the heads of the rats were fixed
in a stereotactic apparatus (Figure 1). A laser Doppler
probe (moor VMS-LDF1, Moor Instruments Inc.,
Devon, Great Britain) was positioned 5.5 mm lateral-
right and 1 mm caudal from the bregma. The cranium
was thinned using a small hand drill (Dremel 300 Series,
Figure 1 Schematic of the experimental setting.
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Doppler probe was positioned in a vertical position and
fixed with a commercially available instant adhesive
(UHU, Bühl, Germany) and activator spray (JAMARA
Modeltechnik, Aichstetten, Germany). The recorded per-
fusion units (PFU) were normalised (100%) to values at
baseline that were recorded 10 min prior to the induction
of ischaemia/hypoxia. The impairment of cerebral autore-
gulation was characterised by the autoregulatory index
(ARI), which was calculated from the slope obtained from
the linear regression analysis of the relative change of
PFU (%) and MAP (%) during reperfusion [23]. The cere-
bral vascular resistance (CVR) was calculated as the ratio
of the MAP to the normalised PFU.
The left somatosensory cortex was partially exposed
by a burr hole located 2–3 mm caudal from the bregma
and 3–4 mm lateral from the midline (Figure 1). The
dura was partially opened with a needle to place a
microdialysis probe with a membrane length of 2 mm,
an outer diameter of 0.5 mm and a cut–off at 20000 DA
(CMA 12, 2 mm membrane length, CMA Microdialysis,
Solna, Sweden). The microdialysis method has been pre-
viously described in detail by Ungerstedt et al. [24]. The
microdialysis catheter was continuously perfused with a
dialysate containing 147 mmol/l NaCl, 2.7 mmol/l KCl,
1.2 mmol/l CaCl2 and 0.85 mmol/l MgCl2 (Perfusion
fluid CNS, CMA Microdialysis) at a flowrate of
2 μl*min-1 using a precision infusion pump (CMA 102,
CMA Microdialysis). The samples were collected in10 min intervals and frozen at -20°C until the analysis.
The thawed and centrifuged dialysate samples were ana-
lysed enzymatically with a chemistry analyser (CMA 600
Microdialysis Analyser, CMA Microdialysis, Schweden)
for lactate, pyruvate, glucose and glutamate concentra-
tions. Prior to the experiments and at the end of the
experiments, the relative recovery rates for each
substance were determined with a calibration solution
(Calibrator, CMA Microdialysis) and applied to the ex-
perimental values. For glutamate, the area under the
concentration curve was calculated to quantify the rela-
tionship between release and uptake.
Experimental protocol
Due to the transient increases in metabolite concentra-
tions from placing the microdialysis probe in the brain,
an equilibration period of 60 min was required. Three
baseline measurements of haemodynamic data and cor-
responding cerebral microdialysates were each sampled
within a 10 min interval. To prevent the rats from
spontaneous breathing triggered by hypoxia, 2 mg kg-1
of rocuronium (Esmeron, Schering-Plough, Kenilworth,
NJ, USA) was injected i.v. The rats were randomly
divided into three groups using an envelope system.
After 10 min of ischaemia, the first group received a
bolus of 24 μg kg-1 levosimendan (SimdaxW 2.5 mg/ml,
Orion Pharma, Espoo, Finland), which was administered
over a period of 20 min, followed by a continuous infu-
sion of 0.2 μg kg-1 min-1 throughout the experiment.
The control group received an equivalent amount of
0.9% NaCl. The sham rats were not subjected to cere-
bral ischaemia/hypoxia but did receive an equivalent
amount of NaCl as the control group. To induce is-
chaemia and hypoxia, both ligatures around the carotid
arteries were closed, and the inspired oxygen concen-
tration was reduced to 6%. Although the haemo-
dynamic variables were recorded during ischaemia/
hypoxia within a 5 min interval, the dialysate was col-
lected over the entire 15 min of hypoxia/ischaemia.
After 15 min, the ligatures were released, and the
inspired oxygen concentration values normalised (30%).
During the following 90 min of reperfusion, the data
were recorded every 10 min, and the dialysate was also
collected during these intervals.
At the end of the measurement period, the abdomen
and thoracic cavity were opened while the rat was in the
supine position. The left ventricle of the beating heart
was cannulated (22 G, Microlance, Becton Dickinson,
Espana), and 4 ml of blood was collected for further
analysis. The animals were transcardially perfused with
50 ml of cold (4°C) Ringers solution. The brain was
excised and cut into seven 2 mm cross-sectional slices.
Two slices were used to calculate the percentage of
water content, and 2 slices (the fourth and fifth) were
Roehl et al. BMC Neurology 2012, 12:81 Page 4 of 10
http://www.biomedcentral.com/1471-2377/12/81immediately snap-frozen in liquid nitrogen and stored at
−80°C for real-time PCR examination. The rest of the
slices were used for further tissue analysis of the levosi-
mendan concentration (Figure 2).
Levosimendan brain tissue concentration
The brain tissue samples were homogenised in 1 ml of
TRIS buffer (Tris-Base 20 mmol/l mM, NaCl 150 mM,
EDTA 1 mM) per gram of wet weight. The homoge-
nates (500 μl per 50 mg of tissue) were extracted at a
neutral pH with ethyl acetate. After evaporation and
resuspension in the mobile phase (acetonitrile/1%
acetic acid), separation of levosimendan was achieved
using a reversed-phase C18 column (the retention time
was 1.4 min) with zonisamide as the internal standard.
Specific ions were detected with an API4000 tandem
MS/MS in the negative multiple reaction mode (Sciex/
Applied Biosystems, Foster City, CA, USA).
S100ß protein analysis
S100ß serum levels at the end of the reperfusion were
analysed by an enzyme-linked immunosorbent assay
(ELISA) using a commercially available kit. The assays
were performed according to the manufacturer’s instruc-
tions (YK150, SCETI, Tokyo, Japan).
Messenger RNA quantification by real-time RT-PCR
Gene expression levels of the pro-inflammatory cyto-
kines tumour necrosis factor α (TNFα), interleukin 6
(IL-6), interleukin 1ß (IL-1β) and intercellular adhesion
molecule 1 (ICAM-1) in the cortex close to the laser
Doppler position were determined by quantitative real-
time polymerase chain reaction (qRT-PCR). Disruption
of the blood–brain barrier was assessed by the gene
expression of claudin 5 (Cldn-5) and tight junction
protein 1 (Tjp-1). Total RNA was extracted using a
commercially available RNA/Protein extraction kit
(NucleoSpinW RNA/Protein, Machery-Nagel, Düren,
Germany) and reverse-transcribed into cDNA using a
high-capacity reverse transcription kit (Applied Biosys-
temsW, Carlsbad, CA, USA). The PCR reaction was per-
formed using 50 ng of cDNA (TaqManW universal PCRFigure 2 A study design diagram: the treatment of the groups related
time points.mix, Applied BiosystemsW) and specific TaqManW probes
for IL-1β (Rn00580432_m1), IL-6 (Rn01410330_m1),
TNF-α (Rn00562055_m1), ICAM-1 (Rn00564227_m1),
Cldn-5 (Rn01753146_s1), Tjp-1 (Rn02116071_s1) and
the housekeeping gene hypoxanthin-guanin-phosphori-
bosyltransferase (HPRT, Rn01527840_m1) on a StepOne-
PlusW Cycler (Applied BiosystemsW). The relative quantity
(RQ) values were calculated according to the ΔΔCt
method, which reflects the differences in the threshold
for each target gene relative to HPRT and the sham-
operated rat.
Statistical analysis
We used a multivariate analysis for repeated measure-
ments and a univariate analysis using Scheffe’s or
Kruskal-Wallis post hoc test for pairwise comparisons be-
tween the groups (depending on the results obtained
from Levene’s test for the equality of variances). A one-
sample t test was used to compare the RQ values with
the sham-operated rats (RQ=1). The effects of ischae-
mia/hypoxia and levosimendan on cerebral autoregulation
were determined using multiple linear regression analysis
(SPSS 19; IBM Corporation, Somers, NY, USA). The RQ
values were plotted as box and whisker graphs displaying
the 5th and 95th percentiles, whereas all of the other
results were presented as the mean and SEM (Prism 5.01,
GraphPad Software, San Diego, CA). A p-value of <0.05
was considered to be statistically significant.
Results
Six of the 30 rats died during the experimental proced-
ure because of several factors, including procedure-
induced injury of the carotid artery, cardiac failure, ven-
tricular fibrillation and brain death. Nine rats were trea-
ted with levosimendan, 9 rats received NaCl (control
group) and sham-operations were performed on 6 rats.
Levosimendan crossed the blood–brain barrier and
reached a tissue concentration of 0.17 ± 0.13 ng g-1.
The effects of ischaemia/hypoxia
During ischaemia/hypoxia, the HR decreased from
407 ± 1 to 325 ± 10 min-1 and MAP from 84 ± 3 toto the procedures. The vertical lines mark the measurement
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mendan and the control group. The LDF signal had
dropped to 6-8% of the baseline values in both of the
groups. No effect of the levosimendan bolus during this
period was evident (Figure 3). Both, the levosimendan
as well as the control group showed a relevant increase
in lactate (+1282± 86 μmol L-1) and glutamate
(+37± 1 μmol L-1) levels, whereas the levels of pyruvate
(−16± 2 μmol L-1) and glucose (−1391± 158 μmol L-1)
were markedly decreased. Thus, the lactate/pyruvate ratio
increased by 5 times during ischaemia/hypoxia (Figure 4).
No differences were found between the groups.
The effects of reperfusion
During early reperfusion, an overshoot in the HR, MAP
and LDF may be detected with peak values after
10–25 min (Figure 3). The levosimendan group showed
a significant delayed (5 min) and smaller increase in the
MAP compared with the control group (72 ± 14 vs.
109 ± 2 mmHg, p = 0.03). In addition, the LDF increase
to the maximum values was delayed by 5 min in the
levosimendan group (p = 0.002) but reached levels that
were comparable with the control group. Moreover, the
mean arterial pressure of the levosimendan-treated rats
remained 12 ± 2 mmHg (p = 0.03) lower throughout
the reperfusion period, whereas no differences in the
LDF amplitudes could be measured between the groups.
Ischaemia/hypoxia in both groups resulted in anHR
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Figuer 3 The effects of levosimendan on the haemodynamics and cer
ischaemia/hypoxia and 90 min of reperfusion (the p-values indicate d
group as assessed.impairment in the cerebral autoregulation, which was
demonstrated by a higher ARI in the control (1.4) and
levosimendan (1.72) group compared with the sham
group (0.38, p < 0.001). There were no differences be-
tween the treatment groups (Figure 5). Although the ele-
vation of the regression line between the LDF and the
MAP was significantly different between the groups, no
effect of levosimendan on the CVR was observed
(Figure 4D). The HR normalised after 90 min and there
were no differences between the groups.
Reperfusion resulted in a further increase in the con-
centration of lactate and pyruvate in the dialysate within
the first 20 min, but this increase was followed by a
continuous decrease (Figure 4A and C). In addition, the
lactate/pyruvate ratio decreased less during early
reperfusion following levosimendan treatment compared
with the control group (144 ± 31 vs. 77 ± 8, p = 0.017,
Figure 4E). Moreover, the glutamate returned to baseline
values within 20 min of reperfusion, whereas glucose
concentrations returned to baseline values within
50 min of reperfusion. Similar to the pyruvate levels, the
glucose levels transiently increased within the first
20 min. Furthermore, the levosimendan-treated animals
displayed more glutamate release (75 ± 19 μmolL-1)
compared with the control (24 ± 28 μmolL-1, p = 0.29)
and sham (-19 ± 11 μmolL-1, p = 0.02, Figure 4D).
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Figure 4 The effects of levosimendan on the extracellular concentrations of lactate [A], glucose [B], pyruvate [C], glutamate [D] and
the lactate/pyruvate ratio [E] during 15 min of bilateral cerebral ischaemia/hypoxia and 90 min of reperfusion. The amount of glutamate
release and uptake was quantified by the area under the curve from plot D (The p-values indicate differences between the control and
levosimendan from an ANOVA; * p < 0.05 vs. control, # p < 0.05 vs. sham).
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(Figure 6A). Although the water content increased
significantly from 68 ± 7% in the sham group to 76 ± 3%
after ischaemia/hypoxia (p = 0.007), there were no differ-
ences between the levosimendan-treated group and the
control group (Figure 6B). Interestingly, cerebral oedema
may be a consequence of reduced expression of Tjp-1
(RQ= 0.84 ± 0.03, p = 0.01, Figure 7A). In addition, we
observed reduced expression of Cldn-5 RQ, but theresults were not significant (RQ= 0.88 ± 0.07, p = 0.09,
Figure 7B). Ischaemia/hypoxia also led to an increased in-
flammatory response in the cortex after 90 min of reper-
fusion. Indeed, we observed pronounced upregulation of
TNFα and IL-1ß by factor 62 (p = 0.01) respectively
8 (p = 0.02) and a moderate threefold upregulation of
ICAM-1 (p = 0.03) in both of the groups, whereas IL-6
levels were only elevated by factor 3.5 in the
levosimendan-treated group (p = 0.02). Beside this,
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Figure 5 A correlation of the relative change of the laser Doppler flow (%LDF) and the mean arterial pressure (%MAP) during
reperfusion. The slope of the linear regression reflects the autoregulatory index (### p < 0.001 vs. sham; ***P < 0.001 vs. control for the intercept).
by an ANOVA and post hoc test at various time points, * p < 0.05). HR – heart rate, MAP – mean arterial pressure, LDF – laser Doppler flow,
CVR – cerebral vascular resistance.
Roehl et al. BMC Neurology 2012, 12:81 Page 7 of 10
http://www.biomedcentral.com/1471-2377/12/81levosimendan did not cause any further significant effects
on gene expression compared with the control group
(Figure 7).
Discussion
The aim of the present study was to evaluate the effects
of levosimendan on brain metabolism, perfusion and in-
flammatory response resulting from a defined hypoxia/
ischaemia injury and to characterise the time-course
during subsequent re-oxygenation. We found that levo-
simendan did not reduce the initial ischaemic/hypoxic
neuronal injury if it was administered after the insult
and during resuscitation.
Ischaemia/hypoxia leads to a primary energy failure that
is accompanied by the dysfunction of ATP-dependent ion
channels (Na+/Ca2+, Ca2+/H+) and an increased intracel-
lular Ca2+ concentration [25,26]. Subsequent glutamate
release activates postsynaptic AMPA and NMDA recep-
tors, which induce intracellular sodium and calcium over-
flow that may be detected prior to anoxic depolarisation
[27]. As a consequence of all this cellular oedema and the
activation of different proteases, lipases, endonucleases
and the generation of free radicals is induced. Import-
antly, the restoration of blood flow and oxygenation will
restore oxidative metabolism within 30 to 60 min,
which suggests a therapeutic window during which the
neurotoxic cascade can be inhibited. Most neurons will
die as a consequence of secondary energy failure, which
occurs 6 to 15 h after injury [4]. The magnitude of pri-
mary cell death is dependent on the severity and dur-
ation of ischaemia/hypoxia and could not be observed
in the neocortex within the first 13 min [28]. In the
present study, we found that an insignificant increase of
s100ß could be observed after 90 min of reperfusion.
Thus, the neuroprotective effects of levosimendan
observed in the neocortex within the first few hours
could only be evaluated based on the monitoring of
triggers of cell death (i.e., glutamate release, energy me-
tabolism and inflammation).Previous studies have demonstrated that it is possible
to reduce glutamate release during ischaemia/hypoxia by
treatment with tiagabine [29], dantrolene [30], nimodi-
pine [31] or magnesium [32]. In principle, the activation
of mKATP channels should result in smaller increases in
intracellular Ca2+ levels and glutamate release during is-
chaemia. Thus, levosimendan may be as effective as
diazoxide [33,34]. Studies have suggested that mKATP
agonists may be beneficial for the treatment of brain dis-
orders that are associated with low ATP levels [35], and
levosimendan has been shown to be neuroprotective in
the spinal cord when applied prior to [13] or during is-
chaemia [14]. Preservation of the energy status displayed
an important mechanism of protection, but was inde-
pendent of vasodilatation [36].
The failure of levosimendan to affect neuroprotection
the parameters determined during the present study
may be related to the low intracerebral concentrations
achieved in the current protocol. Although efficient
serum concentrations for cardiac effects (32 μg/L) were
achieved, the tissue concentration in the brain reached
only 12% of the concentration in the heart. Although
this concentration (0.17 ng g-1) was six times higher
compared with animals with an intact blood–brain bar-
rier [37], it was not sufficient in the in vitro model to re-
duce the primary or secondary injury after trauma. In
the traumatic brain model injury model, a 100-fold
higher concentration was required to achieve significant
affects [15]. The low cerebral concentrations could be a
consequence of the rapid redistribution of the levosi-
mendan bolus [37] and the delayed disruption of the
blood–brain barrier related to the insult [22,38], which
appears to be a prerequisite to achieve higher levosimen-
dan levels within the brain.
Other reasons for the ineffectiveness of levosimendan
might be related to the unique differences of individual
animal models, such as the observation period after the
insult, the methods used to describe the neuronal injury
and the region of interest. For example, the basal ganglia
cerebral oedema
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[28]. The proposed protective effects of levosimendan
might become visible after a longer observation period
and may not be associated with reduced glutamateIL-6
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http://www.biomedcentral.com/1471-2377/12/81increase in inflammation and cerebral oedema and the
disruption of auto regulation and the blood–brain bar-
rier account for cerebral injury. However, if the ischae-
mia/hypoxia is prolonged in this model, animals may die
from cardiovascular complications or brain death. Thus,
modifications to the current protocol for levosimendan
administration and a longer observation period are ne-
cessary for further validation.
The neuroprotective effects of different drugs might
be related to effects on the vasculature. For example, the
protective effects of nimodipine and magnesium are
associated with decreased cerebral blood flow during
reperfusion. Studies have previously shown that con-
trolled reperfusion alone can reduce neuronal injury
[40]; thus, the protective actions of drugs may be
mediated by a similar mechanism. Indeed, levosimendan
affects cerebral perfusion pressure and flow [41]. Al-
though levosimendan delayed reperfusion, we observed
an upward shift in the relationship between CBF and
MAP, which might counterbalance levosimendan’s direct
protective actions. In this context the activation of
mKATP channels and increase of NO release in the ves-
sels by levosimendan was effective and led to vasodila-
tion in the brain as described earlier in an animal model
of subarachnoid haemorrhage [42]. In addition, the
delayed reperfusion during levosimendan treatment may
explain the slower normalisation of the lactate/pyruvate
ratio. The relevance of this difference is questionable,
however, because no differences in the extracellular glu-
cose concentrations were observed.
Other properties associated with cerebral injury were
unaffected by levosimendan treatment. The lack of a
disturbance of cerebral auto regulation and disruption
of the blood–brain barrier resulted in similar cerebral
oedema responses between the groups. Similarly, diaz-
oxide also demonstrated protective effects in this con-
text [43], where activation of KATP channels reduced
the permeability of the BBB and down regulation of
occludin after hypoxia [44]. These differences might be
explained by a diverse affinity to receptor subtypes of
the substances, which have not been investigated in
detail.
Although levosimendan demonstrated anti-inflammatory
actions in sepsis, myocardial reperfusion injury and
ARDS, no effects on the expression of inflammatory
genes in the neocortex were observed. Because inflam-
mation aggravates neuronal injury [45], the protective
effects of levosimendan under inflammatory conditions
are more unlikely.
Conclusion
In conclusion, levosimendan did not exhibit neuropro-
tective actions in the initial phase after experimental
ischaemic/hypoxic cerebral injury. We did not find anyrelevant effects on metabolism, release of glutamate, in-
flammation, auto regulation or the integrity of the
blood–brain barrier. Moreover, no aggravation of brain
injury was found.
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